Elsibucol

Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury[1][2][3].

Product Specifications

CAS Number

[216167-95-2]

UNSPSC

12352005

Target

Integrin; Transmembrane Glycoprotein

Type

Reference compound

Related Pathways

Cytoskeleton; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/elsibucol.html

Purity

99.35

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(CCCOC1=C(C(C)(C)C)C=C(SC(C)(C)SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C=C1C(C)(C)C)O

Molecular Formula

C35H54O4S2

Molecular Weight

602.93

References & Citations

[1]Dussault S, et al. Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation[J]. Atherosclerosis, 2014, 237 (1) : 194-199.|[2]Murata S, et al. Effects of AGI-1096, a novel antioxidant compound with anti-inflammatory and antiproliferative properties, on rodent allograft arteriosclerosis[J]. Transplantation, 2004, 77 (10) : 1494-1500.|[3]First M R, et al. New drugs to improve transplant outcomes[J]. Transplantation, 2004, 77 (9) : S88-S92.